On November 9th, an international medical cannabis symposium, led by Dr. Andrea Small-Howard, will be held in Las Vegas, NV.
LAS VEGAS, Nov. 1, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) announces sponsorship of a one day, November 9th, international medical cannabis symposium, “Innovation in Medical Cannabis Therapies”, under the direction of Dr. Andrea Small-Howard, Chief Science Officer and a member of the Board of Directors for GB Sciences. The symposium will be held in the “Keep Memory Alive” Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Because patients are central to the discussion, the first panel includes a current Parkinson’s patient and his caregiver, and a physician who specializes in the treatment of Parkinson’s disease. They are joined by Jamillah Ali-Rahman, the CEO and founder of Friends of Parkinson’s, and Meredith Patterson, an RN, co-founder of Brainstorm Mind Fitness, and author of “Pillars of Brain Fitness”. Prior registration is advised at https://gbsciences.com/innovation-symposium/.
“To address the question ‘What can the cannabis industry do better or differently to serve the needs of medical patients and to be taken seriously in the medical space?’, we have gathered a broad range of experts in diverse fields related to both the production of and research of cannabis-based medicines,” said Dr. Andrea Small-Howard. “We hope to reveal the new innovations that will be necessary to make safe and effective cannabis-based medicines a reality. Progress may come from the standardization of cultivation or novel extraction methods. Other breakthroughs may come from the combination of cannabis and nanotechnology, or other novel delivery methods. It is a very exciting time to be developing cannabis-based medicines for patients with great unmet clinical needs.”
The primary objective of this symposium is to challenge conventional ways of thinking about medical cannabis from within the cannabis industry. Panels will explore developing better medical cannabis products through innovations in cultivation, extraction, and drug-delivery technologies; along with the essential supporting scientific and clinical research advances necessary to transform medical cannabis products from alternative use to mainstream medical products.
GB Sciences has invited top international and domestic researchers; as well as business leaders and legislators to address the following topics:
Novel Cannabis-based Drug Discovery will be led by Dr. Helen Turner, Vice President of Innovation and Dean of the Division of Natural Sciences and Mathematics at Chaminade University. She is joined by Dr. Norbert Kaminski from Michigan State University, who has studied cannabinoids for 22 years, discovered immune system expression of cannabinoid receptors, and has served on the recent National Academy of Sciences Study on the Health Effects of Cannabis and Cannabinoids. Dr. Maria Halabalaki of the University of Athens, Greece, Dr. Lisa Truong from Oregon State University Ag Center, Dr. Alexander Stokes of the University of Hawai’i, and Dr. Mark Speck from Chaminade University complete this expert research panel.
Challenges and Opportunities in Cannabis Clinical Trials will be directed by Dr. Carlos Rios-Bedoya from McLaren Health. He is joined by Dr. Ziva Cooper of Columbia University, who is a pioneer in the use of double-blind, placebo-controlled methods to study the effects of cannabis, cannabinoids, and opioids. Dr. Cooper was also a co-author of the National Academies of Sciences compendium on the Health Effects of Cannabis. They are joined by Dr. Michael Murphy, CEO, CSO, and Founder of World Wide Clinical Trials and Dr. AmritSeetharam from CurAccel.
Innovations in Cultivation will discuss advances to serve patients who use the cannabis flower as their medicine. The panel is headed by Dr. Philip Elzer, the Executive Associate Dean of the Louisiana State University Ag Center. Dr. Elzer is joined by Dr. Ulrich Reimann-Philipp, the Lead Botanist of GB Sciences Louisiana, who pioneered tissue-culture micro-propagation in cannabis. Completing the panel are Brent Perkins, President & COO, of Scynce LED, Dani Fontaine of the Colorado Hemp Project, and Steve Joyner of the Quantum Shop, manufacturers of modular, portable cannabis pods.
The Extraction Technology Panel will be managed by Tom Arcuragi of GB Sciences and will discuss whether whole-plant extracts or purified individual cannabinoids are better for patients. He will be joined by Dr. EleftheriosPetrakia from the University of Athens, Greece, Dr. Dominick Monaco of GB Sciences, and Dr. Shane Johnson from BayMedica, LLC, a company that is developing bioequivalent cannabinoid production using yeast.
Novel Drug Delivery Systems will be moderated by Dr. Small-Howard of GB Sciences, who will be joined by nanotech researchers Dr. Mercedes Fernandez Arevalo and Dr. Lucia Martin Banderas from the University of Seville, Seville, Spain. They are joined by Scott Schaneville of Striptiva, LLC, and Dr. David Fulper, of CatalentPharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
Medical Cannabis Legislation will discuss legislative challenges and opportunities for supporting cannabis research and serving the needs of medical cannabis patients. The panel is led by Elizabeth Ashford, founder of Ceres Strategies, and will include political figures and advisors including a current Nevada State Senator, Sandra Tiffany, a former Nevada State Senator, and John Davis, President of GB Sciences Louisiana.
The final panel, Changing the Paradigm, will discuss moving cannabis from alternative to mainstream medicine and will be led by Dr. Dominick Monaco of GB Sciences. Brenda Gunsallas of Sahara Wellness and Dessert Aire will join Dr. Monaco and others, to discuss the advancements within the cannabis industry that are necessary to realize the medical promise of the cannabis plant.
Formal and informal opportunities for meeting and questioning panelists will be plentiful.
John Poss, CEO and Chairman of the Board of GB Sciences comments, “GB Sciences is proud to sponsor this annual symposium which brings together a disparate community of scientists, educators, business owners and legislators and in so doing; changes the landscape of the potentiality of medical cannabis.”
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
Tom Arcuragi, EVP, email@example.com